InflaRX  In March 2024, InflaRx Biopharmaceutical (IFRX) announced that it will pursue two initial immuno-dermatology indications with INF904 in a single Phase 2a basket trial expected to begin by the end of 2024, with initial data anticipated in the summer of 2025.  The trial will be a multi-center, open-label study on 75 patients. We will be evaluating multiple INF904 dosing regimens over . . . …